Assessment of serum lipid metabolism index and cytokine levels in patients with type 2 diabetes mellitus complicated by coronary heart disease after telmisartan combined with lipid-lowering drug treatment

摘要

Objective: To study the effect of telmisartan combined with lipid-lowering drug therapy onserum lipid metabolism index and cytokine levels in patients with type 2 diabetes mellituscomplicated by coronary heart disease. Methods: A total of 106 patients with type 2 diabetesmellitus complicated by coronary heart disease who were treated in our hospital betweenSeptember 2013 and October 2016 were collected and then divided into the control group (n=55)who received conventional treatment + lipid-lowering drug treatment and the observation group(n=51) who received conventional treatment + lipid-lowering drug + telmisartan treatmentafter the therapies were reviewed. Before and after treatment, serum levels of lipid metabolismindexes, inflammatory mediators and oxidative stress indexes were compared betweentwo groups of patients. Results: Before treatment, the differences in serum levels of lipidmetabolism indexes, inflammatory mediators and oxidative stress indexes were not statisticallysignificant between two groups of patients. After treatment, serum TG and LDL-C levels inobservation group were lower than those in control group while HDL-C level was higher thanthat in control group; serum inflammatory mediators IL-6, IL-8, HMGB1 and TNF-α levelswere lower than those in control group; serum oxidative stress indexes MDA and ROS levelswere lower than those in control group while GSH-Px level was higher than that in controlgroup. Conclusion: Telmisartan combined with lipid-lowering drug therapy can effectivelyoptimize the lipid metabolism and reduce the systemic inflammatory response and oxidativestress response in patients with type 2 diabetes mellitus complicated by coronary heart disease.